Cross-sectional comparisons of patient-reported disease control, disease severity and symptom frequency in children with atopic dermatitis

2017 ◽  
Vol 177 (4) ◽  
pp. e114-e115 ◽  
Author(s):  
J. Chang ◽  
W.B. Bilker ◽  
O. Hoffstad ◽  
D.J. Margolis
Keyword(s):  
Atopic Dermatitis ◽  
Disease Control ◽  
Disease Severity ◽  
Cross Sectional ◽  
Patient Reported ◽  
Symptom Frequency ◽  
Control Disease

O060 Cross-sectional study of disease control among adults with atopic dermatitis and impact on patient-reported burden

2016 ◽  
Vol 117 (5) ◽  
pp. S19-S20
Author(s):  
E. Simpson ◽  
E. Guttman-Yassky ◽  
D. Margolis ◽  
S. Feldman ◽  
A. Qureshi ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Disease Control ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Patient Reported

scholarly journals Discordance Between Physician- and Patient-Reported Disease Severity in Adults with Atopic Dermatitis: A US Cross-Sectional Survey

2017 ◽  
Vol 18 (6) ◽  
pp. 825-835 ◽  
Author(s):  
Wenhui Wei ◽  
Peter Anderson ◽  
Abhijit Gadkari ◽  
Stuart Blackburn ◽  
Rachel Moon ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Disease Severity ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Patient Reported

Association of Touch Avoidance with Disease Severity and Quality of Life in Psoriasis Patients

2017 ◽  
Vol 2 (3) ◽  
pp. 57-63 ◽  
Author(s):  
April W. Armstrong ◽  
Jennifer C. Cather ◽  
Carle F. Paul ◽  
Emily Edson-Heredia ◽  
Baojin Zhu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Disease Severity ◽  
Linear Models ◽  
Logistic Models ◽  
Patient Reported Outcome Measures ◽  
Cross Sectional ◽  
Patient Reported ◽  
Touch Avoidance ◽  
The Impact

Background and Objective Previous large studies have highlighted the impact of psoriasis on health-related quality of life (HRQoL) but not on interpersonal touch. This survey assessed the prevalence of touch avoidance among psoriasis patients, and its relationship to clinical characteristics and HRQoL. Methods Using an online, cross-sectional study with a standardized questionnaire, psoriasis patients reported their level of touch avoidance. The relationships between touch avoidance, patient-reported outcome measures, and patient demographics were analyzed using linear models for continuous outcomes and logistic models for categorical outcomes. Results Touch avoidance was reported by 48.2% of participants. Higher levels of touch avoidance were associated with worse HRQoL, depression, and itch outcomes (p<.001 for all). The strongest indicators of touch avoidance were HRQoL score (p<.001) and depression score (p<.001). Conclusion Nearly half of psoriasis patients report avoidance of touch. Those who had worse disease severity, HRQoL, and depression reported higher levels of touch avoidance.

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis

2018 ◽  
Vol 22 (1_suppl) ◽  
pp. 10S-16S ◽  
Author(s):  
Melinda J. Gooderham ◽  
Robert Bissonnette ◽  
Parbeer Grewal ◽  
Perla Lansang ◽  
Kim A. Papp ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Disease Severity ◽  
Rating Scale ◽  
Numerical Rating Scale ◽  
Life Quality ◽  
Severity Index ◽  
Adult Patients ◽  
Physician Global Assessment ◽  
Atopic Dermatitis Severity ◽  
Patient Reported

Clinicians rely on clinical measures to define the severity of atopic dermatitis and assess outcomes of therapy. These measures can be objective (ie, physician assessments of disease severity) or subjective (ie, patient-reported symptoms and quality of life outcomes). In this review, the most commonly used tools for assessing atopic dermatitis severity in adult patients are presented and compared. These include Eczema Area and Severity Index (EASI); SCORing Atopic Dermatitis (SCORAD); Physician Global Assessment (PGA); body surface area (BSA); Atopic Dermatitis Severity Index (ADSI); Six Area, Six Sign Atopic Dermatitis (SASSAD); Patient Oriented Eczema Measure (POEM); Dermatology Life Quality Index (DLQI); and pruritus Numerical Rating Scale (NRS). Available severity strata for the tools are summarized, although the use of severity strata in clinical practice is not recommended. Since both objective and subjective assessments of disease severity are important to assess, consideration of clinical characteristics such as disease recurrence or persistence, as well as location of the affected areas, should be considered in the overall judgement of disease severity and consideration of therapy choice.

scholarly journals Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan

2021 ◽  
Vol 10 (24) ◽  
pp. 5732
Author(s):  
Yukari Okubo ◽  
Ann Chuo Tang ◽  
Sachie Inoue ◽  
Hitoe Torisu-Itakura ◽  
Mamitaro Ohtsuki
Keyword(s):  
Disease Severity ◽  
Treatment Satisfaction ◽  
Secondary Analysis ◽  
Severity Index ◽  
Treatment Goals ◽  
Cross Sectional ◽  
Logistic Regression Models ◽  
Patient Reported ◽  
Related Quality ◽  
Health Related

Background: Previously, our cross-sectional observational study in Japan revealed high (68%) discordance within treatment goals between psoriasis patients and their physicians. Objective: This secondary analysis aimed to determine whether patient and physician users of biologics have higher treatment goals than users of non-biologics. Methods: A survey for both patients and physicians on background characteristics, disease severity, treatment goals, treatment satisfaction, and health-related quality of life was conducted at 54 sites. Association between treatment goals and biologic/non-biologic users was assessed using ordinal logistic regression models. Results: In total, 449 patient-physician pairs agreed to participate; 425 completed the survey and were analyzed. More biologic users than non-biologic users reported complete clearance (Psoriasis Area and Severity Index 100) as a treatment goal (patient-reported: 23.6% vs. 16.1%; physician-reported: 26.9% vs. 2.2%). Biologic users were significantly associated with higher treatment goals than non-biologic users (patient-reported: 1.8 (1.15–2.87) (odds ratio (9 5% CI)), p = 0.01; physician-reported: 11.0 (5.72–21.01), p < 0.01). Among biologic users, higher treatment goals were associated with higher treatment satisfaction (patient- and physician-rated); lower treatment goals were associated with back lesions and increasing patient age (patient-rated) and higher disease severity (physician-rated). Conclusion: Use of biologics among patients with psoriasis was associated with higher treatment goals. Further use of biologics contributed to treatment satisfaction. Appropriate treatment goals that are shared among patients and their physicians may improve treatment outcomes.

Sign in / Sign up

Export Citation Format

Share Document